Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | AGXT | P21549 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2970007 | 0.89 | IDO1 (0.59) | IDO1AGXTCHRM3MAOBTAAR1 | |
| SCHEMBL3454548 | 0.86 | IDO1 (0.56) | IDO1AGXTTDP1L3MBTL1MAOB | |
| SCHEMBL23872295 | 0.86 | CYP4F2 (0.47) | — | |
| SCHEMBL7387588 | 0.84 | IDO1 (0.54) | IDO1AGXTTDP1L3MBTL1CHRM3 | |
| SCHEMBL4734636 | 0.84 | IDO1 (0.57) | IDO1AGXTTDP1L3MBTL1MAOB | |
| SCHEMBL23640522 | 0.84 | IDO1 (0.57) | IDO1AGXTTDP1L3MBTL1CHRM3 | |
| SCHEMBL7386591 | 0.83 | IDO1 (0.53) | IDO1AGXTTDP1L3MBTL1CHRM3 | |
| SCHEMBL10458644 | 0.82 | IDO1 (0.59) | IDO1AGXTCHRM3MAOBTAAR1 | |
| SCHEMBL6205292 | 0.82 | IDO1 (0.62) | IDO1AGXTCHRM3MAOBMRGPRX4 | |
| SCHEMBL3768643 | 0.81 | IDO1 (0.71) | IDO1AGXTCHRM3MAOBTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020103381-A1 | Method for the synthesis of pyrazolines | CHEMRX ADVANCED TECHNOLOGIES, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001040193-A1 | METHOD FOR THE SYNTHESIS OF PYRAZOLINES | CHEMRX ADVANCED TECHNOLOGIES, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103381-A1 | Method for the synthesis of pyrazolines | CYP2F1, CYP2E1, CYP3A7 | IDO1 859/4885AGXT 1400/4885TDP1 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.